Gemcitabine With Curcumin for Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT00192842
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
- locally advanced or metastatic adenocarcinoma of the pancreas
- no prior chemotherapy
- performance status 0-2
- adequate hematology and chemistry
Read More
Exclusion Criteria
- serious concurrent medical condition
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method time to tumor progression
- Secondary Outcome Measures
Name Time Method response rate survival clinical benefit toxicity